Amisulpride for very late-onset schizophrenia-like psychosis: the ATLAS three-arm RCT.

@article{Howard2018AmisulprideFV,
  title={Amisulpride for very late-onset schizophrenia-like psychosis: the ATLAS three-arm RCT.},
  author={Robert J. Howard and Elizabeth Cort and Robert K. Bradley and Emma L. Harper and Linda A. Kelly and Peter A. Bentham and Craig W. Ritchie and Suzanne J. Reeves and Waleed Fawzi and Gill Livingston and Andrew Sommerlad and Sabu Oomman and Ejaz Nazir and Ramin Nilforooshan and Robert Barber and Chris Fox and Ajay Verma Macharouthu and Pranathi Ramachandra and Vivek Pattan and John Sykes and Valerie H. Curran and C Katona and Tom Dening and Martin Knapp and Renee Romeo and Richard Gray},
  journal={Health technology assessment},
  year={2018},
  volume={22 67},
  pages={
          1-62
        }
}
BACKGROUND Very late-onset (aged ≥ 60 years) schizophrenia-like psychosis (VLOSLP) occurs frequently but no placebo-controlled, randomised trials have assessed the efficacy or risks of antipsychotic treatment. Most patients are not prescribed treatment. OBJECTIVES The study investigated whether or not low-dose amisulpride is superior to placebo in reducing psychosis symptoms over 12 weeks and if any benefit is maintained by continuing treatment thereafter. Treatment safety and cost… CONTINUE READING
BETA
7
Twitter Mentions